Single-Center Evaluation of the Pharmacokinetics of WCK 5222 (Cefepime-Zidebactam Combination) in Subjects with Renal Impairment
| Autor: | Grigor Mamikonyan, Christopher J. Kemper, Stephane DeGraff, Allan Xu, Ashima Bhatia, Anasuya Patel, Mushtaque Mastim, Rajesh Chavan, James Chiou, Richard A. Preston, H. David Friedland, Ravindra D. Yeole |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Male
medicine.medical_specialty medicine.medical_treatment Cefepime Urology Renal function urologic and male genital diseases Single Center 03 medical and health sciences Cyclooctanes Pharmacokinetics Medicine Humans Penicillin-Binding Proteins Pharmacology (medical) Renal Insufficiency Dialysis Aged Pharmacology 0303 health sciences Time zero 030306 microbiology business.industry Middle Aged Anti-Bacterial Agents Cephalosporins Infectious Diseases Kidney Failure Chronic Female Hemodialysis business beta-Lactamase Inhibitors Azabicyclo Compounds medicine.drug Zidebactam |
| Zdroj: | Antimicrobial agents and chemotherapy. 63(1) |
| ISSN: | 1098-6596 |
| Popis: | WCK 5222 is a novel β-lactam–β-lactam-enhancer combination of cefepime (FEP) and zidebactam (ZID). ZID is a novel β-lactam enhancer with a dual action of binding to Gram-negative penicillin-binding protein 2 (PBP2) and β-lactamase inhibition. WCK 5222 is being developed as a new therapeutic option for the treatment of complicated multidrug-resistant Gram-negative pathogen infections. We investigated the effect of renal impairment on the pharmacokinetics (PK) and safety of WCK 5222 in 48 subjects based on Cockcroft-Gault-estimated creatinine clearance (CL(CR)). We enrolled mild (n = 6; CL(CR), 60 to |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|